FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2625846788> ?p ?o ?g. }

• W2625846788 endingPage "761" @default.
• W2625846788 startingPage "753" @default.
• W2625846788 abstract "Background & AimsWe assessed the diagnostic performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi-center study, using central histology as reference.MethodsWe collected data from 113 adults with NASH participating in a multi-center, randomized, double-masked, placebo-controlled, phase 2b trial to compare the efficacy cross-sectionally and longitudinally of obeticholic acid vs placebo. Hepatic steatosis was assessed at baseline and after 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners from different manufacturers, at 1.5T or 3T). We compared steatosis estimates by PDFF vs histology. Histologic steatosis grade was scored in consensus by a pathology committee. Cross-validated receiver operating characteristic (ROC) analyses were performed.ResultsAt baseline, 34% of subjects had steatosis grade 0 or 1, 39% had steatosis grade 2, and 27% had steatosis grade 3; corresponding mean PDFF values were 9.8%±3.7%, 18.1%±4.3%, and 30.1%±8.1%. PDFF classified steatosis grade 0–1 vs 2–3 with an area under the ROC curve (AUROC) of 0.95 (95% CI, 0.91–0.98), and grade 0–2 vs grade 3 steatosis with an AUROC of 0.96 (95% CI, 0.93–0.99). PDFF cut-off values at 90% specificity were 16.3% for grades 2–3 and 21.7% for grade 3, with corresponding sensitivities of 83% and 84%. After 72 weeks' of obeticholic vs placebo, 42% of subjects had a reduced steatosis grade (mean reduction in PDFF from baseline of 7.4%±8.7%), 49% had no change in steatosis grade (mean increase in PDFF from baseline of 0.3%±6.3%), and 9% had an increased steatosis grade (mean increase in PDFF from baseline of 7.7%±6.0%). PDFF change identified subjects with reduced steatosis grade with an AUROC of 0.81 (95% CI, 0.71–0.91) and increased steatosis grade with an AUROC of 0.81 (95% CI, 0.63–0.99). A PDFF reduction of 5.15% identified subjects with reduced steatosis grade with 90% specificity and 58% sensitivity, whereas a PDFF increase of 5.6% identified those with increased steatosis grade with 90% specificity and 57% sensitivity.ConclusionsBased on data from a phase 2 randomized controlled trial of adults with NASH, PDFF estimated by MRI scanners of different field strength and at different sites, accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a reference. We assessed the diagnostic performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi-center study, using central histology as reference. We collected data from 113 adults with NASH participating in a multi-center, randomized, double-masked, placebo-controlled, phase 2b trial to compare the efficacy cross-sectionally and longitudinally of obeticholic acid vs placebo. Hepatic steatosis was assessed at baseline and after 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners from different manufacturers, at 1.5T or 3T). We compared steatosis estimates by PDFF vs histology. Histologic steatosis grade was scored in consensus by a pathology committee. Cross-validated receiver operating characteristic (ROC) analyses were performed. At baseline, 34% of subjects had steatosis grade 0 or 1, 39% had steatosis grade 2, and 27% had steatosis grade 3; corresponding mean PDFF values were 9.8%±3.7%, 18.1%±4.3%, and 30.1%±8.1%. PDFF classified steatosis grade 0–1 vs 2–3 with an area under the ROC curve (AUROC) of 0.95 (95% CI, 0.91–0.98), and grade 0–2 vs grade 3 steatosis with an AUROC of 0.96 (95% CI, 0.93–0.99). PDFF cut-off values at 90% specificity were 16.3% for grades 2–3 and 21.7% for grade 3, with corresponding sensitivities of 83% and 84%. After 72 weeks' of obeticholic vs placebo, 42% of subjects had a reduced steatosis grade (mean reduction in PDFF from baseline of 7.4%±8.7%), 49% had no change in steatosis grade (mean increase in PDFF from baseline of 0.3%±6.3%), and 9% had an increased steatosis grade (mean increase in PDFF from baseline of 7.7%±6.0%). PDFF change identified subjects with reduced steatosis grade with an AUROC of 0.81 (95% CI, 0.71–0.91) and increased steatosis grade with an AUROC of 0.81 (95% CI, 0.63–0.99). A PDFF reduction of 5.15% identified subjects with reduced steatosis grade with 90% specificity and 58% sensitivity, whereas a PDFF increase of 5.6% identified those with increased steatosis grade with 90% specificity and 57% sensitivity. Based on data from a phase 2 randomized controlled trial of adults with NASH, PDFF estimated by MRI scanners of different field strength and at different sites, accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a reference." @default.
• W2625846788 created "2017-06-23" @default.
• W2625846788 creator A5019378601 @default.
• W2625846788 creator A5023720526 @default.
• W2625846788 creator A5025819859 @default.
• W2625846788 creator A5034542011 @default.
• W2625846788 creator A5035067430 @default.
• W2625846788 creator A5038164406 @default.
• W2625846788 creator A5052059601 @default.
• W2625846788 creator A5053930455 @default.
• W2625846788 creator A5056997652 @default.
• W2625846788 creator A5058421287 @default.
• W2625846788 creator A5058529918 @default.
• W2625846788 creator A5064449939 @default.
• W2625846788 creator A5070639714 @default.
• W2625846788 creator A5072014736 @default.
• W2625846788 creator A5073573770 @default.
• W2625846788 date "2017-09-01" @default.
• W2625846788 modified "2023-10-15" @default.
• W2625846788 title "Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis" @default.
• W2625846788 cites W1583960324 @default.
• W2625846788 cites W1963682935 @default.
• W2625846788 cites W1969486929 @default.
• W2625846788 cites W1974062643 @default.
• W2625846788 cites W1978274444 @default.
• W2625846788 cites W1979959518 @default.
• W2625846788 cites W1983496515 @default.
• W2625846788 cites W1988826453 @default.
• W2625846788 cites W1990726393 @default.
• W2625846788 cites W2002349285 @default.
• W2625846788 cites W2019810874 @default.
• W2625846788 cites W2022296797 @default.
• W2625846788 cites W2050385934 @default.
• W2625846788 cites W2059251195 @default.
• W2625846788 cites W2066473433 @default.
• W2625846788 cites W2067135721 @default.
• W2625846788 cites W2067740038 @default.
• W2625846788 cites W2076355272 @default.
• W2625846788 cites W2076450230 @default.
• W2625846788 cites W2079100340 @default.
• W2625846788 cites W2101530263 @default.
• W2625846788 cites W2106768039 @default.
• W2625846788 cites W2106871563 @default.
• W2625846788 cites W2129011084 @default.
• W2625846788 cites W2138306815 @default.
• W2625846788 cites W2138525610 @default.
• W2625846788 cites W2150687196 @default.
• W2625846788 cites W2154312373 @default.
• W2625846788 cites W2195637511 @default.
• W2625846788 cites W2268168587 @default.
• W2625846788 cites W2462595066 @default.
• W2625846788 doi "https://doi.org/10.1053/j.gastro.2017.06.005" @default.
• W2625846788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5695870" @default.
• W2625846788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28624576" @default.
• W2625846788 hasPublicationYear "2017" @default.
• W2625846788 type Work @default.
• W2625846788 sameAs 2625846788 @default.
• W2625846788 citedByCount "195" @default.
• W2625846788 countsByYear W26258467882017 @default.
• W2625846788 countsByYear W26258467882018 @default.
• W2625846788 countsByYear W26258467882019 @default.
• W2625846788 countsByYear W26258467882020 @default.
• W2625846788 countsByYear W26258467882021 @default.
• W2625846788 countsByYear W26258467882022 @default.
• W2625846788 countsByYear W26258467882023 @default.
• W2625846788 crossrefType "journal-article" @default.
• W2625846788 hasAuthorship W2625846788A5019378601 @default.
• W2625846788 hasAuthorship W2625846788A5023720526 @default.
• W2625846788 hasAuthorship W2625846788A5025819859 @default.
• W2625846788 hasAuthorship W2625846788A5034542011 @default.
• W2625846788 hasAuthorship W2625846788A5035067430 @default.
• W2625846788 hasAuthorship W2625846788A5038164406 @default.
• W2625846788 hasAuthorship W2625846788A5052059601 @default.
• W2625846788 hasAuthorship W2625846788A5053930455 @default.
• W2625846788 hasAuthorship W2625846788A5056997652 @default.
• W2625846788 hasAuthorship W2625846788A5058421287 @default.
• W2625846788 hasAuthorship W2625846788A5058529918 @default.
• W2625846788 hasAuthorship W2625846788A5064449939 @default.
• W2625846788 hasAuthorship W2625846788A5070639714 @default.
• W2625846788 hasAuthorship W2625846788A5072014736 @default.
• W2625846788 hasAuthorship W2625846788A5073573770 @default.
• W2625846788 hasBestOaLocation W26258467881 @default.
• W2625846788 hasConcept C126322002 @default.
• W2625846788 hasConcept C126838900 @default.
• W2625846788 hasConcept C142724271 @default.
• W2625846788 hasConcept C143409427 @default.
• W2625846788 hasConcept C204787440 @default.
• W2625846788 hasConcept C27081682 @default.
• W2625846788 hasConcept C2776175330 @default.
• W2625846788 hasConcept C2776954865 @default.
• W2625846788 hasConcept C2778772119 @default.
• W2625846788 hasConcept C2779134260 @default.
• W2625846788 hasConcept C3018708256 @default.
• W2625846788 hasConcept C71924100 @default.
• W2625846788 hasConcept C90924648 @default.
• W2625846788 hasConceptScore W2625846788C126322002 @default.
• W2625846788 hasConceptScore W2625846788C126838900 @default.
• W2625846788 hasConceptScore W2625846788C142724271 @default.

• next